FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

1. Name and Address of Reporting Person^{\star}

(First)

(Middle)

NOVARTIS AG

LICHTSTRASSE 35

(Last)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

Sectio obligat	n 16. Form 4 or tions may contil tion 1(b).	Form 5	C 171	Fil				ection 16(a 30(h) of the						34		ll l	ated av	erage burde sponse:	en 0.5
		Reporting Person*	*					ne and Tick N THEI				[A	LRN]		elationship of ck all applica Director	ible)	g Perso	10% Ov	wner
(Last) C/O NO WSJ-200	VARTIS IN	First) TERNATIONA	(Middle) L AG		0	7/05/	2017	rliest Transi				u/Voa	r)	6 In	Officer (below)	give title	Filing	Other (steeled)	
(Street) BASEL	V	78	CH-4002		4.	. II AIII	enum	eni, Dale o	i Originai	riieu	(MOHUI/Day	y/ rea	1)	Line	Form file	ed by One	e Repoi	rting Persor One Repor	n
(City)	(5	State)	(Zip)																
1. Title of	Security (Ins		able I - No	2. Trans Date (Month/	actio	on	2A. E Exec if any	Deemed ution Date,	3. Transa Code (action	4. Securit	ies A	cquired	(A) or	5. Amoun	ly	Form	Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	Transaction (Instr. 3 au				(11341.4)
Common Stock				07/05	07/05/2017						2,277,515		A	(1)	2,277,515		D ⁽²⁾		
Common	Stock			07/05					P		266,667		A	\$15	2,544	,182		D ⁽²⁾	
			Table II -					ies Acqı varrants							Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	Co	ode (ction Instr.	Deri Sec Acq or D	umber of vative urities uired (A) isposed of Instr. 3, 4 5)	6. Date E Expiratio (Month/I	on Dat		of S Und Der	itle and ecuritie lerlying ivative S tr. 3 and	Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporter	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficia Ownershi t (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title		Amount or Number of Shares		Transact (Instr. 4)	tion(s)		
Series C Preferred Stock	(1)	07/05/2017			С			2,967,025	(1)		(1)		nmon ock	298,583	\$0.00	0		D ⁽²⁾	
Series C-2 Preferred Stock	(1)	07/05/2017			С			4,238,607	(1)		(1)		nmon ock	426,547	\$0.00	0		D ⁽²⁾	
Series D Preferred Stock	(1)	07/05/2017			С			6,781,770	(1)		(1)		nmon ock	682,476	\$0.00	0		D ⁽²⁾	
Series E-2 Preferred Stock	(1)	07/05/2017			С			2,644,558	(1)		(1)		nmon ock	266,132	\$0.00	0		D ⁽²⁾	
Series E-3 Preferred Stock	(1)	07/05/2017			С			2,293,829	(1)		(1)		nmon ock	230,837	\$0.00	0		D ⁽²⁾	
Series F Preferred Stock	(1)	07/05/2017			С			3,705,882	(1)		(1)		nmon ock	372,937	\$0.00	0		D ⁽²⁾	
		Reporting Person* tures Ltd	*																
(Last) C/O NO WSJ-200		(First) TERNATIONA	(Middl L AG	e)															
(Street) BASEL		V8	CH-4	1002															
(City)		(State)	(Zip)																

(Street) BASEL	V8	CH 4056
(City)	(State)	(Zip)

Explanation of Responses:

- 1. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- 2. The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
- 3. Novartis Bioventures Ltd., a wholly-owned indirect subsidiary of Novartis AG, acquired 266,667 shares of Common Stock in the Issuer's initial public offering.

Remarks:

/s/ Bartosz Dzikowski, authorized signatory 07/05/2017

/s/ Stephan Sandmeier, authorized signatory 07/05/2017

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.